



**Vascular Implant Surveillance and Interventional Outcomes Network
(VISION) “Think Tank”**

Meeting Agenda (DRAFT)

Monday, September 10, 2018
 FDA Headquarters, White Oak Campus
 Building 66, Room G514
 10903 New Hampshire Avenue
 Silver Spring, MD 20993

8:00 am to 8:30 am	Registration	
AM Session 1: What do you see in VISION? Moderator: Industry (TBD)		
8:30 am to 9:00 am	Introduction	Philip Goodney Dartmouth-Hitchcock Medical Center and The Dartmouth Institute Art Sedrakyan Weill Cornell Medical Center
9:00 am to 9:20 am	Development of CRNs: Benefits to the FDA Mission	Danica Marinac-Dabic US Food and Drug Administration
9:20 am to 9:40 am	Registry Partners Incentive’s and Roles	Jens Eldrup-Jorgensen Society for Vascular Surgery Patient Safety Organization
9:40 am to 9:55 am	<i>Commentary/Discussion</i>	SVS VQI Leaders Marc Shermerhorn , Beth Israel Deaconess Medical Center and Harvard Medical School Matthew Mell , UC Davis Graham Roche-Nagle , University of Toronto

9:55 am to 10:10 am	Break	
AM Session 2: Integrating VISION for maximal impact – Moderator: Misti Malone (FDA)		
10:10 am to 10:40 am	RAPID/SPEED: Development, accomplishments, and how they might integrate further with VISION	Yu-Ching Cheng , US Food and Drug Administration Daniel Bertges University of Vermont Medical Center
10:40 am to 11:40 am	EDUCATE: (NESTcc Demonstration Project): Goals, potential impact, and mechanisms for development of CRN-derived datasets	Kathy Blake , AMA, NEST Governance Committee Philip Goodney Dartmouth-Hitchcock Medical Center and The Dartmouth Institute Pablo Morales , US Food and Drug Administration
11:40 am to 12:00 noon	<i>Commentary/Discussion</i>	Scott Williams , Cook Medical Keely Scamperle , Gore Tiessa Simoes , Medtronic Danica Marinac-Dabic , FDA
12:00 pm to 1:00 pm	Lunch	
PM Session 1: Using VISION data to improve vascular care Moderator: TBD		
1:00 pm to 1:15 pm	TEVAR outcomes assessment	Grace Wang University of Pennsylvania
1:15 pm to 1:30 pm	Lower extremity PAD outcomes assessment	Jessica Simons University of Massachusetts Medical School
1:30 pm to 1:45 pm	Open AAA outcomes assessment	Sarah Deery Beth Israel Deaconess Medical Center
1:45 pm to 2:00 pm	Partnership or Risk – where industry can use CRN deliverables	Scott Williams , Cook Medical Roberta Bloss , Gore Tiessa Simoes , Medtronic
2:00 pm to 2:20 pm	<i>Commentary/Discussion</i>	SVS VQI and FDA Leaders

		Salvatore Scali , University of Florida, and UFL Health-Shands Hospital Leila Mureebe , Duke University School of Medicine, Durham VAMC Brian Pullin/Misti Malone , FDA
2:20 pm to 2:35 pm	Break	
PM Session 2: Sustainability and Trials and Benchmarking Moderator: TBD		
2:35 to 2:50 pm	ICVR and national trials – opportunity for CRN-derived data to branch out	Adam Beck University of Alabama
2:50 – 3:15	Value of PGs/OPCs for regulatory decision-making	TBD (FDA)
Wrap-Up		
3:15 pm to 3:35 pm	What's Next	Philip Goodney Dartmouth-Hitchcock Medical Center and The Dartmouth Institute
3:35 pm - 4:00 pm	Vision for VISION CRN & Final Closing	Art Sedrakyan Weill Cornell Medical Center